These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27217435)

  • 1. Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
    Bagai A; Bhatt DL; Eikelboom JW; Mancini GB; Cohen EA; Vijayaraghavan R; Cheema AN; Udell JA; Niznick J; Tanguay JF; Verma S; Mehta SR
    Circulation; 2016 May; 133(21):2094-8. PubMed ID: 27217435
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel: the data, the experience, and the controversies.
    Sadanandan S; Singh IM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2Y12 inhibitors in acute coronary syndrome: when to give them and when to prolong their use.
    Grotti S; Bolognese L
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e9-e12. PubMed ID: 29538137
    [No Abstract]   [Full Text] [Related]  

  • 5. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
    Harding SA; Holley A; Wilkins B; Fairley S; Simmonds M; Larsen PD
    Intern Med J; 2017 Nov; 47(11):1298-1305. PubMed ID: 28857445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome.
    Deharo P; Cuisset T
    Trends Cardiovasc Med; 2020 May; 30(4):198-202. PubMed ID: 31182263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thirty days only double antiplatelet therapy after drug-eluting stenting: could a 'short-term' treatment be advantageous?
    Casella G; Resciniti E; Gallo P
    J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e21-e25. PubMed ID: 29045308
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of dual antiplatelet therapy in acute coronary syndrome.
    Wilson SJ; Newby DE; Dawson D; Irving J; Berry C
    Heart; 2017 Apr; 103(8):573-580. PubMed ID: 28249994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
    Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
    Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
    Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will this trial change my practice? ACCOAST - early loading with a novel P2Y12 inhibitor in patients with an acute coronary syndrome.
    De Palma R; James S; Jüni P; Cuisset T
    EuroIntervention; 2014 Jul; 10(3):408-10. PubMed ID: 25042271
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should all stent patients have prolonged dual antiplatelet therapy?
    Kirtane AJ; King SB
    JACC Cardiovasc Interv; 2015 May; 8(6):873-875. PubMed ID: 25999115
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting.
    Brener SJ; Serruys PW; Morice MC; Mehran R; Kappetein AP; Sabik JF; Liu Y; Dressler O; Ben-Yehuda O; Stone GW
    J Am Coll Cardiol; 2018 Oct; 72(17):2086-2087. PubMed ID: 30336833
    [No Abstract]   [Full Text] [Related]  

  • 19. Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test.
    Tello-Montoliu A; Albaladejo P; Hernández-Romero D; Taboada R; Albacete CL; Arribas JM; Jara R; Veliz A; López-García C; Cánovas S; Valdés M; Rivera-Caravaca JM; Marín F
    Circ Cardiovasc Interv; 2018 Dec; 11(12):e007264. PubMed ID: 30525983
    [No Abstract]   [Full Text] [Related]  

  • 20. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
    Bernlochner I; Byrne RA; Kastrati A; Sibbing D
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.